Quantum Biopharma (QNTM) Total Current Liabilities (2018 - 2026)

Quantum Biopharma has disclosed Total Current Liabilities across 9 years of filings, most recently posting $16.3 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $16.3 million, up 58.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.3 million (up 58.02% YoY), and the FY2025 annual result was $6.1 million, down 9.29% from the prior year.
• Total Current Liabilities came in at $16.3 million for Q1 2026 at Quantum Biopharma, up from $6.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $16.3 million in Q1 2026 to a low of $4.6 million in Q4 2023.
• The 5-year median for Total Current Liabilities is $6.7 million (2024), against an average of $8.5 million.
• Across the five-year window, Total Current Liabilities plunged 41.69% in 2023 and jumped 162.64% in 2025, its largest moves.
• Quantum Biopharma's Total Current Liabilities stood at $7.8 million in 2022, then tumbled by 41.69% to $4.6 million in 2023, then soared by 46.29% to $6.7 million in 2024, then decreased by 9.29% to $6.1 million in 2025, then soared by 169.81% to $16.3 million in 2026.
• The last three Total Current Liabilities figures came in at $16.3 million (Q1 2026), $6.1 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.